

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

SWOG/ Support	STUDY	O R P E E G N	ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	DATE OF FIRST REG.	# of ACT. INSTs	# of CURR IRBs	
						LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS				
SWOG	S1320-Adv, BRAF mut, Inter v Contin	1	Y 1	Lead-in Continuous Dosing	280	185	62	38	19	10	6	09/19/2014	229	102
						185	62	38	19	10	6			
		2	Y 2	Continuous Dosing	280	74	25	17	7	2	1	09/19/2014		
			3	Intermittent Dosing		71	23	10	5	1	0			
						145	48	27	12	3	1			
	S1404-Melan, Adv, HD-IFN/Ipilimumab vs MK-3475	1	N 1	Tissue for PD-L1 testing	1378	1426	836	296	0	0	0	11/10/2015	390	170
						1426	836	296	0	0	0			
		2	Y 2	FDA approved regimen	1378	678	430	168	26	0	0	11/10/2015		
			3	MK-3475 (Pembrolizumab)		667	409	157	27	0	0			
						1345	839	325	53	0	0			
	S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro)	1	Y 1	MK-3475 (pembrolizumab)	77	3	3	2	0	0	0	02/06/2017	73	31
						3	3	2	0	0	0			
	S1616-MELAN, Adv, Ipilimumab ± Nivolumab	1	Y 2	Nivolumab + Ipilimumab	94	2	2	2	2	2	1	10/23/2017		54
						2	2	2	2	2	1			
Yes	EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T	1	E	Total Registrations		23	13	7	6	1	0	11/03/2015	350	144
						23	13	7	6	1	0			
		2	E	Total Registrations		5	3	2	1	0	0	11/03/2015		
						5	3	2	1	0	0			
	EA6141-Melan, Adv, Nivolumab+Ipi ± Sargmostim	1	E	Total Registrations		36	23	7	0	0	0	03/25/2016	312	126
						36	23	7	0	0	0			
No	E3612-MELAN, Adv Ipilimumab±Bevacizumab	1	E	Total Registrations		6	1	1	1	0	0	02/16/2015	116	42
						6	1	1	1	0	0			

**19-NOV-2017 6:10**  
**MELAN Open Studies with No Registrations**

<u>Study</u>	<u>Registration/Phase</u>	<u>Open Date</u>
S1607 MELAN, Adv, T-VEC, MK-3475	1 Registration	02-Oct-17